Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novozymes A/S    NZYM B   DK0060336014

NOVOZYMES A/S

(NZYM B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at DKK 335.1 DKK in weekly data.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 335.1 DKK
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
Ratings chart
Sector Specialty Chemicals
1st jan.Capitalisation (M$)Investor Rating
NOVOZYMES A/S2.03%16 354
ECOLAB INC.-1.83%60 626
SIKA AG2.40%39 633
GIVAUDAN SA-3.35%37 573
EMS-CHEMIE HOLDING AG-1.76%22 135
SYMRISE AG-6.69%16 675
UMICORE21.05%13 926
NITTO DENKO CORPORATION1.52%13 358
CHINA JUSHI CO., LTD.19.74%12 914
CRODA INTERNATIONAL PLC-2.61%12 149
ZHEJIANG HUAFENG SPANDEX CO..35.18%9 751
JOHNSON MATTHEY PLC23.51%7 878
ZHEJIANG LONGSHENG GROUP CO..13.29%7 718
IMCD N.V.4.60%7 550
WACKER CHEMIE AG3.77%7 326
CLARIANT AG3.43%7 240
More Results
Financials
Sales 2020 14 103 M 2 307 M 2 307 M
Net income 2020 2 862 M 468 M 468 M
Net Debt 2020 4 380 M 717 M 717 M
P/E ratio 2020 35,0x
Yield 2020 1,52%
Capitalization 99 933 M 16 354 M 16 348 M
EV / Sales 2020 7,40x
EV / Sales 2021 7,19x
Nbr of Employees 6 180
Free-Float 71,9%
Upcoming event on NOVOZYMES A/S
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes